Fox Chase Cancer Center News

PHILADELPHIA (July 13, 2017) – Fox Chase Cancer Center announced the results of its 2017 Supported Pilot Project and Supported High Throughput Screening Project competitions. Several researchers will receive funding as part of the center’s Cancer Center Support Grant (CCSG) from the National Cancer Institute. Three pilot projects and one high throughput screening project were recognized.

PHILADELPHIA (July 11, 2017) -The Pain & Palliative Care Program at Fox Chase Cancer Center is proud to offer a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia and Temple University Hospital. The one-year program is approved by the Accreditation Council for Graduate Medical Education.

PHILADELPHIA (July 10, 2017) – Researchers at Fox Chase Cancer Center have identified the specific ways in which the CCDC170 gene may influence breast cancer risk or progression. The laboratories of Xiaowei Chen, PhD, and Richard A. Katz, PhD, have discovered a function for the CCDC170 protein that suggests a mechanism related to the hallmark changes in cell movement seen in breast cancer.

PHILADELPHIA, (July 5, 2017) – Fox Chase Cancer Center announced the addition of the Discovery™ NM750b Molecular Breast Imaging (MBI) system as a complementary diagnostic tool to detect breast cancer after a questionable mammogram. MBI is now available to help physicians in the Philadelphia area detect early stage cancers even in dense breast tissue. 

​PHILADELPHIA, (June 30, 2017) – Alexander Kutikov, MD, has been appointed the new chief of the Division of Urologic Oncology at Fox Chase Cancer Center. He will assume his new responsibilities on July 1, 2017.

PHILADELPHIA (June 27, 2017) – Analyzing a panel of 25 genes, researchers found mutations in genes associated with increased risk of breast or ovarian cancer in approximately seven percent of women tested through a large commercial laboratory. Depending on the gene, they found increased risk between two- and six-fold for breast cancer and two- and forty-fold for ovarian cancer.

PHILADELPHIA (June 27, 2017) – It is important that all patients who have completed cancer treatment have a wellness plan in place as they transition from treatment to recovery.

Modern Healthcare writes that those on the list “stand out for the scope of their executive responsibilities, personal achievements, innovation and commitment to their communities.”